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Application of Novel and Existing Methods to Identify Genes with
Evidence of Epigenetic Association: Results from GAW20
Abstract
Background: The rise in popularity and accessibility of DNA methylation data to evaluate
epigenetic associations with disease has led to numerous methodological questions. As part of
GAW20, our working group of 8 research groups focused on gene searching methods.
Results: Although the methods were varied, we identified 3 main themes within our group.
First, many groups tackled the question of how best to use pedigree information in
downstream analyses, finding that (a) the use of kinship matrices is common practice, (b)
ascertainment corrections may be necessary, and (c) pedigree information may be useful for
identifying parent-of-origin effects. Second, many groups also considered multimarker versus
single-marker tests. Multimarker tests had modestly improved power versus single-marker
methods on simulated data, and on real data identified additional associations that were not
identified with single-marker methods, including identification of a gene with a strong
biological interpretation. Finally, some of the groups explored methods to combine single-
nucleotide polymorphism (SNP) and DNA methylation into a single association analysis.
Conclusions: A causal inference method showed promise at discovering new mechanisms of
SNP activity; gene-based methods of summarizing SNP and DNA methylation data also
showed promise. Even though numerous questions still remain in the analysis of DNA
methylation data, our discussions at GAW20 suggest some emerging best practices.
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METHODOLOGY Open Access
Application of novel and existing methods
to identify genes with evidence of
epigenetic association: results from GAW20
Angga M. Fuady1†, Samantha Lent2†, Chloé Sarnowski2† and Nathan L. Tintle3*
From Genetic Analysis Workshop 20
San Diego, CA, USA. 4-8 March 2017
Abstract
Background: The rise in popularity and accessibility of DNA methylation data to evaluate epigenetic associations
with disease has led to numerous methodological questions. As part of GAW20, our working group of 8 research
groups focused on gene searching methods.
Results: Although the methods were varied, we identified 3 main themes within our group. First, many groups
tackled the question of how best to use pedigree information in downstream analyses, finding that (a) the use of
kinship matrices is common practice, (b) ascertainment corrections may be necessary, and (c) pedigree information
may be useful for identifying parent-of-origin effects. Second, many groups also considered multimarker versus single-
marker tests. Multimarker tests had modestly improved power versus single-marker methods on simulated data, and
on real data identified additional associations that were not identified with single-marker methods, including
identification of a gene with a strong biological interpretation. Finally, some of the groups explored methods to
combine single-nucleotide polymorphism (SNP) and DNA methylation into a single association analysis.
Conclusions: A causal inference method showed promise at discovering new mechanisms of SNP activity; gene-based
methods of summarizing SNP and DNA methylation data also showed promise. Even though numerous questions still
remain in the analysis of DNA methylation data, our discussions at GAW20 suggest some emerging best practices.
Keywords: GAW20, DNA methylation, Single nucleotide polymorphism, Multimarker tests, Ascertainment, Epigenetics,
Family data
Background
Over the last decade, the proliferation of genetic measure-
ment technologies and computational capacity has
spurned a host of methodological innovations in down-
stream data analyses. The popular and widely used
genome-wide association study (GWAS) has had a large
impact on our understanding of the heritable component
of numerous phenotypes [1]. However, recent techno-
logical advances have brought us high-coverage genome
sequence, genome-wide transcriptomics, copy-number
polymorphism, proteomics, and metabolomics data.
Genome-wide methylation data have also become
available via “off-the-shelf” array-based measurement
technologies. The increased accessibility of genome-wide
methylation measurements, combined with an increased
appreciation for the role of epigenetic variation in pheno-
typic expression, has ushered in a new era of methodo-
logical innovation.
Standard methods of methylation analysis use a general
linear modeling approach to estimate the association
between methylation levels and phenotypic variation. Typ-
ically, a separate model is fit for each cytosine-phosphate-
guanine (CpG) site of interest. Despite the seemingly
straightforward nature of this approach, it raises
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numerous methodological questions. For example, what
are appropriate methods for accounting for relatedness
and sample ascertainment? Are standard methods from
GWAS (eg, kinship adjustment) sufficient? Or, are more
sophisticated methods necessary? Although next-gener-
ation sequencing data and rare-variant analyses have
brought multimarker analysis methods into the main-
stream, we know little about the potential efficacy of these
methods in the context of DNA methylation data. Yet
another question of interest involves appropriate ways to
integrate multiple data sources; for example, if methyla-
tion data (eg, DNA methylation probes) and genomic data
(eg, single-nucleotide polymorphism [SNP] markers) are
available, how best could this data be integrated to
maximize the ability to explain phenotypic variation and
identify candidate regions of the genome for future study?
As part of GAW20, 8 research groups were assigned
to the Epigenetics: Gene Searching working group.
These 8 groups from around the world met in San
Diego, CA, USA to share and discuss their individual
methodological innovations and analytic evaluations
around the theme of identifying genes with evidence of
epigenetic effects on phenotypes. In the following sec-
tions, we describe the 8 individual contributions, their
methods and their results, and summarize 3 primary
themes from our discussions.
Methods
The Epigenetics: Gene Searching group at GAW20 con-
sisted of 8 separate contributions. Groups analyzed a
mix of real (6 contributions) and simulated (2 contribu-
tions) GAW20 data [2]. The real GAW20 data set con-
sisted of both methylation data and high-density
lipoprotein cholesterol (HDL-C)/triglyceride (TG) levels
before and after treatment with fenofibrate, a drug used
to assist in lowering cholesterol and TG levels [2]. A full
set of SNP genotypes was also available for most individ-
uals in the study. Real data was obtained from the Gen-
etics of Lipid Lowering Drugs and Diet Network
(GOLDN) study [3]. Data was simulated based on the
real data and included 200 independently simulated sets
of posttreatment TG and methylation levels, with hy-
pothesized effects of genetic variation and methylation
on TG/HDL-C levels [2]. The majority of groups used
multimarker methods (6 of 8 contributions) and/or can-
didate gene/marker approaches (5 of 8 contributions).
We now briefly describe the methods used by each of
the 8 separate contributions. In most cases, additional
information about each contribution, beyond that pre-
sented here, can be gleaned by reading the related publi-
cations for each individual contribution; citations, where
available, are provided.
Fuady et al. [4] aimed to investigate the relationship
between change in TG and change in methylation after
treatment. They focused on strategies of ascertainment
correction for families. From the real data set, they ana-
lyzed 421 individuals who had data on both TG and
methylation levels. They defined the change in methyla-
tion at each CpG site as the difference between methyla-
tion values at baseline and follow-up. Change in TG was
computed similarly, as the difference between the mean
log-transformed TG at baseline and posttreatment. They
evaluated 2 ascertainment bias correction methods and
compared them to a naïve approach that ignores
ascertainment.
Huisman et al. [5] evaluated the performance of novel
gene-based test association methods on GAW20 simu-
lated genome-wide data (N = 670) as compared to
single-marker tests. They used the lmekin function from
the coxme package in R [6] to predict the change in
log-transformed TG levels from baseline to follow-up,
adjusting for familial relationships. Then they regressed
the residuals from the previous model on genetic vari-
ants and methylation scores. They defined sets of candi-
date genes and, for each gene, created different scores by
aggregating beta coefficients or p values for SNPs or
DNA methylation probes. They assessed statistical sig-
nificance of genes using permutations.
Lent et al. [7] proposed a new method, GlobalP, to de-
tect differentially methylated regions (DMRs), regions
enriched for association with a phenotype, and compared
this new method to 3 existing methods: Bumphunter [8],
comb-p [9], and DMRcate [10]. Lent et al. applied Bum-
phunter to a subset of unrelated individuals (pretreatment
N = 176, posttreatment N = 176) and all other methods to
all individuals with both genotype and methylation data
(pretreatment N = 679, posttreatment N = 403). Two
epigenome-wide association studies (EWAS), with pre-
treatment and posttreatment TG as the outcomes, were
performed in the related sample, adjusting for empirical
kinship estimated from genotypes, to calculate summary
statistics for input into DMRcate, comb-p, and GlobalP.
Sarnowski et al. [11] performed parent-of-origin effect
association analyses of genetic variants with TG (pre-
treatment TG, posttreatment TG and pretreatment and
posttreatment TG difference) followed by association
analyses with DNA methylation probes in the real
GAW20 family data set. From the real data, they ana-
lyzed 823 genotyped individuals from 173 families
(715,787 SNPs). They used a linear regression approach
implemented in the Quantitative Transmission Disequi-
librium Test (QTDT) software [12] to detect parent-
of-origin associations of genetic variants with TG. Then,
they investigated if the detected parent-of-origin effects
were associated with TG-associated CpG sites using lin-
ear mixed effect models. Finally, they performed causal
inference tests [13] to assess whether methylation medi-
ated the observed parent-of-origin effects.
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Wang et al. [14] explored 2 methods to investigate the
gene-based changes of DNA methylation and the associ-
ations with lipid changes induced by treatment: the
median methylation level test (MMLT [15]) and the
sequence kernel association test (SKAT [16]). They ana-
lyzed 446 individuals at 423,180 CpG sites. The median
methylation level of all the CpG sites within a region
was calculated to summarize the typical methylation
level of the gene. They performed linear mixed effect re-
gression models to investigate the association between
change in methylation and change of either TG or
HDL-C after 3 weeks of intervention. Then they used
the SKAT to evaluate the association of change in TG or
HDL-C with a set of CpG sites.
Wu et al. [17] extended the adaptive sum of powered
score (aSPU) test for methylation data [18]. The sum of
powered score (SPU) test is a score based test with 2 pa-
rameters: a power index and component weights. Special
cases include the Burden test [19] when the power index
is 1 and the SKAT test [16] when the power index is 2.
The aSPU test is an extension to SPU that does not re-
quire choosing a power index, but still requires the
choice of component weights. Wu et al. proposed using
the inverse variance of CpG sites as the weights for
aSPU. Wu et al. modeled the association between
pretreatment methylation and TG using gene-based
aSPU tests and compared this to a standard EWAS im-
plemented in GMMAT (generalized linear mixed model
association test) [20]. All models used the related sam-
ple, adjusting for empirical kinship estimated from
genotypes.
Xu et al. [21] proposed new methods to identify SNP
markers and CpG variants associated with a phenotype
of interest (TG or HDL-C) using an iterative regression
or an extreme value approach. The iterative regression
strategy is a single-marker (single-SNP or single-CpG
site) method, whereas the extreme value strategy is a
gene-based method. They used 418 cases and 687 con-
trol individuals and examined 467,225 SNPs. Combina-
tions of the selected SNP/CpG sites (iterative regression
strategy) or candidate genes (extreme values strategy)
were tested using a score test proposed by Chapman et
al. [22]. To potentially improve power, a hybrid approach
of these strategies was also considered. They compared
the performance of each approach with the correlated
method [23].
Zhao et al. [24] focused their investigation on
gene-based association between DNA methylation and
lipid-level changes in chromosomes 11 and 19. They ex-
plored 2 complementary region-based association tests.
They used 420 related individuals for whom pretreat-
ment methylation data were available and, in separate
analyses, 176 unrelated individuals. Methylation data on
chromosomes 11 and 19 were grouped into 1484 and
1698 genes, respectively, and transformed using the logit
function. The principal components of explained vari-
ance (PCEV [25]) and a variance component (VC) score
test [26] were used to analyze the unrelated individuals.
Family data were analyzed via an extension of a
VC-score test [26].
Results
Theme 1: Family versus unrelated individuals
Six contributions in our group specifically explored the
family data to perform association analyses (Fuady et
al..., Lent et al., Sarnowski et al., Wang et al., Wu et al.,
Zhao et al). In the contribution of Fuady et al., family
data was used to investigate the association between
lipid changes and methylation changes after treatment
using various family-based ascertainment correction
approaches. Zhao et al. employed family structure to
identify gene-based association between chromosomes
11 and 19 DNA methylation sites and change in lipid
levels. Parent-of-origin effect association analyses were
performed by Sarnowski et al., using the family data.
Wang et al. explored 2 independent methods to in-
vestigate the association between changes in methyla-
tion and drug response in families. Wu et al. used
family data to assess the relationship between baseline
methylation and TG levels. Lent et al. compared vari-
ous methods to analyze the association between
DMRs and TG level using family data. In all contri-
butions, empirical kinship was used to adjust for family
structure.
Ascertainment correction
Ascertainment correction plays a role not only for fam-
ilies but also for unrelated individuals who were selected
from the pedigree. The available data set in GAW20 is
based on the GOLDN study, which recruited families
with at least 2 coronary heart disease events and a family
risk score of 0.5 or higher [2, 27]. The multiple-case
family design is enriched for the outcome variable (pri-
mary phenotype). Some work has been done when mod-
eling the primary phenotype to address the
ascertainment bias [28]. When modeling the secondary
phenotype, it is also necessary to correct for the ascer-
tainment, especially when the primary and the secondary
phenotype are correlated [29].
Fuady et al. explored 2 existing statistical methods to
take ascertainment into account for multiple-case fam-
ilies. The first method is the secondary phenotype ap-
proach [30]. In this approach, the ascertainment process
is corrected using the retrospective likelihood and joint
model between the primary and secondary phenotype.
They choose metabolic syndrome (MetS) as the primary
phenotype and methylation as the secondary phenotype.
The second approach is an ascertainment correction
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based on proband as implemented in SOLAR (Sequen-
tial Oligogenic Linkage Analysis Routines) [31]. The cor-
rection was performed by conditioning the likelihood of
each pedigree with the trait value of the proband [32].
In the contribution of Zhao et al., the ascertainment
correction was implemented by constructing principal
components (PCs) of genome-wide methylation levels
using 2000 probes randomly sampled from all chromo-
some. PCs were used to adjust for known and unknown
confounders. Moreover, it is also useful to improve the
validity of the VC-score test. The top 4 methylation-de-
rived PCs were used as an additional covariate in the
model. An extended VC-score test [26] was used to in-
corporate the family structure in the data set. This
approach decomposes the total variation of the phenotype
into variation explained by region-methylation profiles
and residual variation. In particular, it assumes that the
phenotypic similarity between individuals is totally
captured by the region-methylation similarity, after the as-
certainment adjustment via the PCs.
To compare the ascertainment correction approach in
the multiple-case family, Fuady et al. computed the aver-
age distance of the effect of the change in TG on the
change in methylation from a combination of 3 ap-
proaches. The average distance between the secondary
phenotype and the naïve approach is smaller when the
CpGs are not associated with the primary phenotype
MetS (0.169 vs 0.418). This suggests that using MetS in-
stead of coronary heart disease as the primary phenotype
captures a part of selection mechanism. For CpG sites
associated with the primary phenotype MetS, it is neces-
sary to use the more complex secondary phenotype ap-
proach. For the other CpG sites, both approaches should
provide the same results. Zhao et al. found that inclusion
of the top 4 methylation-derived PCs was important in
controlling for unknown confounding. Without this ad-
justment, the distribution of p values was very biased
from what would be expected under the null. In this
analysis, the logit transformation did not seem to pro-
vide any improvements. Moreover, as a consequence of
the increase in sample size, the family-data analysis iden-
tified more significant genes than the analysis using un-
related individuals.
Modeling the family structure
Four contributors used the linear mixed effect model to
account for familial relatedness. Fuady et al. and Wang
et al. used this model to assess the relationship between
change in methylation and change in lipid levels in the
naïve approach and MMLT, respectively. Specifically,
they used lmekin function provided by coxme package in
R [2] to conduct the analysis. In MMLT [15], the out-
come was the lipid change while the change in median
methylation was treated as an independent variable. In
the naïve approach, methylation data was treated as
dependent variable and the lipid changes as an inde-
pendent variable. Sarnowski et al. used the linear mixed
effect model provided by the QTDT software [12] to
perform parent-of-origin effect association analyses with
TG levels at baseline, follow-up, or on the difference be-
tween baseline and follow-up. They modeled the pheno-
type of the offspring as a function of covariates and
genotype by taking parental original of each allele into
consideration. In the contribution of Zhao et al., a linear
mixed effect model was used in the family-based
VC-score test [26].
In the parent-of-origin association analysis, Sarnowski
et al. found a paternal effect of rs301621-G on the pre-
treatment and posttreatment of TG difference. They also
found a maternal effect of this SNP on cg10206250
methylation levels. The observed paternal effect of this
SNP is induced by treatment. However, this effect is not
mediated by DNA methylation at cg10205250.
Analyzing unrelated individuals
To analyze unrelated individuals, Zhao et al. used PCEV
[25], which seeks to identify the linear combination of
outcomes that maximizes the proportion of the variance
being explained by the covariate. They contrasted the
method using the VC-score test [26], which reduces sig-
nificantly the model degrees of freedom compared to
standard multivariate regression models. They restricted
the analysis to genes on chromosome 11. The VC-score
approach identified 1 gene, SPTY2D1, which was signifi-
cantly associated with HDL-C changes. Using the PCEV
approach, 1 gene, NAV2, was significantly associated
with TG changes.
Theme 2: Multimarker versus single-marker tests
Single-marker EWAS, which model the association be-
tween a phenotype and each CpG site individually, are
widely used but may be underpowered owing to the
small effect sizes often seen in epigenetic studies [33]
and the high multiple testing burden of DNA methyla-
tion arrays [34]. Six papers in our group explored multi-
marker methods to test the association between a
phenotype and set of CpG sites (Lent et al..., Huisman et
al., Wang et al., Zhao et al., Xu et al., and Wu et al).
These methods can be categorized into gene score ap-
proaches, collapsing methods, and combination of EWAS
summary statistics. The authors used real and simulated
data to compare these multimarker association tests to the
standard single-marker EWAS and evaluated consistency
of results from different multimarker approaches.
Gene score approaches
One way to reduce the multiple testing burden with
methylation array data is to create gene scores and
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perform 1 test of association per gene rather than 1 test
per CpG site. Wang et al. implemented 1 gene score
method, MMLT [15], using the real data set, whereas
Huisman et al. tested several gene score methods using
the simulated data set. Wang et al. did not find any
genes where the change in median methylation before
and after treatment was associated with the change in ei-
ther HDL-C or TG. Huisman et al. found that gene
scores derived from single-marker EWAS p values—
minimum gene p value, sum of log p values, and sum of
squared log p values—had more power to detect simu-
lated associations than single-marker EWAS. Gene
scores derived from single-marker EWAS estimates of
effect—maximum absolute value, median absolute value,
sum, and sum of squared estimates of effect—had lower
power than single-marker EWAS and higher Type I
error.
Collapsing methods
Like single-marker EWAS, gene score methods model
the association between a phenotype and a single sum-
mary measure of gene methylation. An alternative way
to perform gene-based tests is to model the association
between a phenotype and all CpG sites in a gene. We
refer to these approaches, jointly modeling the associ-
ation between a phenotype and methylation at a set of
CpG sites, as collapsing methods. Four papers in our
group used collapsing method approaches to directly
model the association between a phenotype and set of
CpG sites in the real data.
Xu et al. performed a score test to evaluate the associ-
ation between simulated posttreatment methylation and
TG in candidate genes [6]. All other collapsing
method groups employed a VC-based approach. Wang
et al., Wu et al., and Zhao et al. all applied a SKAT
[16] or adjusted SKAT (ASKAT) [26] test to the real
data, and Wu et al. proposed an extension to a
VC-based approach, aSPU [18].
Zhao et al. restricted their analysis to genes on
chromosomes 11 and 19 and employed 2 multimarker
approaches, SKAT and PCEV [25], described in
Theme 1. There was some overlap in the top results
of the SKAT and PCEV approaches: OR8H3 was in
the top 5 genes associated with change in HDL-C for
both methods, and P2RX3 was in the top 5 genes as-
sociated with change in TG for both methods. Wang
et al. also performed a SKAT test of association
across the whole epigenome and identified 2 genes,
GZF1 and C18orf19, where change in methylation be-
fore and after treatment was associated with change
in HDL-C after correcting for multiple testing with a
false discovery rate.
Wu et al. first performed an EWAS to quantify the
association between methylation and pretreatment TG
at each CpG site. They then performed 2 aSPU tests per
gene, once using equal weights and once using inverse
CpG sites variance weights, and compared to the EWAS
for pretreatment TG. Additionally, 1 aSPU test per gene
using the inverse variance weights was performed with
change in methylation before and after treatment as the
outcome. Using the inverse of the CpG site variance as
the CpG site weights, Wu et al. identified 1 gene,
CPT1A, associated with pretreatment TG after Bonfer-
roni correction. This gene was also identified in the
single-marker EWAS, but was not identified by aSPU
when using equal CpG site weights.
Combination of EWAS summary statistics
Lent et al. compared 1 novel method of combining
EWAS summary statistics to perform regional tests, Glo-
balP, to 3 existing methods: Bumphunter [8], comb-p [9]
and DMRcate [10]. For GlobalP, 178,015 regions were
defined from gene and CpG island annotations. A test
statistic for each region using the EWAS z-statistics was
calculated, taking into account partial between CpG site
M-values, and region p values were corrected for mul-
tiple testing using a false discovery rate. There was no
overlap in regions identified by Bumphunter and other
methods. GlobalP and comb-p identified regions in
CPT1A associated with TG both before and after treat-
ment. The single-marker EWAS also identified an asso-
ciation in CPT1A.
Theme 3: Combining SNPs and DNA methylation probes
Three papers in our group combined both SNPs and
DNA methylation probes (Huisman et al......., Sarnowski et
al., Xu et al) to perform association analyses. One
paper was an application of an existing method, the
QTDT [12], in the real GAW20 data set (Sarnowski
et al) and 2 papers proposed new methods (Huisman
et al., Xu et al). In this section, we address 3 different
questions: (a) Why use both SNPs and DNA methyla-
tion probes? (b) How to combine both SNPs and
DNA methylation probes? and (c) What lessons did
we learn from using both SNPs and DNA methylation
probes?
Why use both SNPs and DNA methylation probes?
Sarnowski et al. jointly analyzed SNPs and DNA methy-
lation probes to better understand the biological mecha-
nisms underlying parent-of-origin effects. Huisman et al.
compared the performances of novel multimarker
methods versus single-marker test using statistics based
on SNPs or DNA methylation probes. Xu et al. devel-
oped 3 strategies to search for both genetics variants and
CpG site variants associated with a quantitative trait
(TG or HDL-C) in multiple genes: an iterative regression
(single-SNP or single-CpG-based method), an extreme
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values approach (gene-based method), and a hybrid
approach.
How to combine both SNPs and DNA methylation
probes?
We identified 2 common steps in the 3 papers: (a) a fil-
tering of the number of SNPs and probes (CpG sites) to
be tested and (b) a joint test of SNPs and DNA methyla-
tion probes.
Filtering of the number of SNPs and DNA methylation
probes
One statistical reason for the filtering of the number of
SNPs and DNA methylation probes is to reduce the
number of SNP-CpG pairs tested and address the mul-
tiple testing issue. Another biological reason is to study
the effect and interaction of SNPs and probes that are
located in a same region (cis-effects). This first step was
done based on either (a) GWAS and EWAS results (Sar-
nowski et al...) or (b) candidate genes (Huisman et al.,
Xu et al).
Sarnowski et al. tested the association of SNPs with
TG under parent-of-origin effects using QTDT and
selected suggestive associations based on an agnostic
approach or a candidate approach (GWAS regions re-
ported associated with TG). Then they selected CpG
sites located nearby the suggestive SNPs (±50 kb) and
tested the association with TG. Finally, they selected
nominally associated CpG sites and performed a causal
inference test [13] for each SNP-CpG pair. Huisman et
al. selected candidate genes based on GAW20 simulation
data. They defined 3 distinct groups of genes: 5 major
effect genes with a causal SNP with high heritability,
34 minor effect genes with a causal SNP with modest
heritability, and 39 randomly selected noncausal genes
with no causal SNPs. For a genetic variant that was
causal according to the GAW20 simulation [2], they
selected the causal DNA methylation probe provided
by the solutions, whereas for a noncausal genetic
variant they selected the closest DNA methylation
probe. Xu et al. used 2 different filtering strategies. In
their iterative regression approach, few candidate
SNPs and/or CpG sites highly correlated with trait
values were tested first and a best variant was se-
lected. The regression was repeated against the re-
sidual to select additional SNPs and/or CpG sites. In
their extreme values strategy, the individuals with the
top 5% value of the quantitative trait were used to se-
lect candidate genes with at least 1 CpG site.
Joint test of SNPs and DNA methylation probes
The second step was a joint test of SNPs and DNA
methylation probes. Joint tests that combine both SNP
and methylation data were used by Sarnowski et al. and
Huisman et al.:
CpG ¼ βSNP  SNP þ βTG  ΔTG ð1Þ
ΔTG ¼ βSNP  SNP þ βCpG  CpG ð2Þ
Sarnowski et al. used eqs. (1) and (2) in the causal in-
ference test to determine if a CpG probe mediates the
association between a SNP and TG under a
parent-of-origin effect model. Huisman et al. used test
(2) as a data preprocessing step to get beta coefficients
statistics or p values (for SNP and CpG sites) to aggre-
gate in their multimarker methods. For each gene, they
created 4 scores by aggregating beta coefficients or p
values for SNPs or DNA methylation probes (sum of ab-
solute values, sum of squares, maximum of absolute
values, and median of absolute values in the spirit of
other papers exploring aggregation methods [35–37]).
Xu et al. used a multimarker approach to test the
combined SNPs/CpG sites or candidate genes from the
iterative regression and the extreme values strategy (a
score test developed by Chapman et al. [6]). They com-
pared the performances of the different approaches
(iterative regression, extreme values strategy, or a hybrid
approach) with the correlated method [23].
What lessons have we learned from the GAW20 data set
when using both SNPs and DNA methylation probes?
Sarnowski et al. identified 22 SNPs with suggestive
parent-of-origin effects on TG (P ≤ 10− 5) and 18 DNA
methylation probes located nearby these SNPs were
found associated with TG (P ≤ 0.05). One SNP-probe
pair presented evidence of parent-of-origin effect: the
SNP rs301621 was associated with the difference be-
tween pretreatment and posttreatment TG when trans-
mitted by the father (P = 1.2 × 10− 5). This same SNP was
associated with the methylation levels of cg10206250
when transmitted by the mother (P = 0.01). Using a
causal inference test, the authors showed that the ob-
served parent-of-origin effect of rs301621 was not medi-
ated by DNA methylation at cg10206250. Huisman et al.
performed gene-based tests based on SNP or CpG
estimates from the joint test of SNP and CpG on TG.
They found an average power of 0.48 and a Type I error
of 0.04 when using the SNP statistics and a power of
0.06 and a Type I error of 0.04 when using the CpG sta-
tistics. Their results also suggested that methods run on
major effect genes (with causal SNPs) were detecting
more “signal” than on minor effect genes (with no causal
SNPs). Finally, they found that single-marker tests out-
performed gene-based tests in general. Xu et al. found
that the correlated method and the hybrid approach had
correct Type I errors for TG association analyses, but
were conservative for HDL-C. The other methods were
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more conservative for both traits. The patterns of power
comparison for TG and HDL-C were consistent. From
the most powerful to the least powerful, the methods
were the hybrid approach, the iterative regression strat-
egy, the extreme values strategy, and the correlated
method.
Discussion
Numerous methodological questions exist about how
best to analyze genome-wide methylation data. How-
ever, based on 8 individual contributions investigating
related questions about analysis strategies, we have
identified a few preliminary recommendations and
conclusions.
First, as it is the case for GWAS, adjustment for famil-
ial relationships appears to be both standard practice
and an effective approach for methylation studies.
Accounting for ascertainment bias, however, appears less
mainstream, though it has a potentially measurable ef-
fect on conclusions. Further exploration of methods and
impact on analyses is suggested.
Second, the use of multimarker methods appears
promising as a way to reduce multiple testing penalties,
aggregate effects, and provide more precise biological
interpretation. Further work is needed, however, to iden-
tify an optimal or “gold-standard” set of multimarker
methods to become part of a standard analysis pipeline
for EWAS. Currently, numerous methods are available
and a comprehensive understanding of the pros and
cons of these methods remains elusive.
Third, the simultaneous analysis of methylation data
and genetic markers also appears promising, as a way to
both uncover true biological mechanisms and improve
statistical power. However, it is worth noting that the in-
tegration of multiple data sources brings with it the
challenge of knowing how to best integrate multiple
types of data. Precise specification of statistical models
and how they reflect biological mechanism is important.
It remains easy to grab an off-the-shelf method that
results in unexpected behavior. We remain optimis-
tic, however, that such approaches are both neces-
sary and hold great promise for the future of genetic
epidemiology.
Fourth, the field of genetic epidemiology continues to
wrestle with the promise of ever larger data sets that are
pitched to provide enough data so that a lack of statis-
tical power should no longer be an excuse for an inabil-
ity to identify causal relationships. However, as is
evidenced by the GAW20 workshop data sets, data sets
with “only” hundreds to thousands of individuals who
have a complete set of phenotypic and genetic measure-
ments remains an acute reality. With this mind,
methodological innovations, which seek to maximize
biological interpretation and statistical power despite
complete data on only hundreds or thousands of individ-
uals remains an important area of future research.
Conclusions
Conclusions of theme 1
Three conclusions can be drawn from theme 1. First,
modeling family data using a kinship matrix is now
standard practice. Second, an ascertainment correction
for multiple-case families and unrelated individuals
seems to be necessary, although there may be no
agreement on how best to do them. Finally, pedigree
information may be useful for identifying parent-of-ori-
gin effects.
Conclusions of theme 2
In the simulated data, Xu et al. and Huisman et al. found
that multimarker methods had modestly increased
power to detect epigenetic associations compared to
single-marker methods. The simulated epigenetic effects
in the GAW20 simulated data set were not multimarker
effects, so the increase in power was likely owing to a
reduced multiple-testing burden, indicating that multi-
marker methods are useful even without multimarker
effects. Huisman et al. also found that multimarker tests
based on effect size had increased Type I error.
In the real data, Wang et al. and Zhao et al. found that
multimarker tests identified associations that single-
marker EWAS did not. There was little overlap in results
between groups because of the different choices in time
points and phenotypes modeled. However, Lent et al.
and Wu et al. both found that CPT1A was associated
with TG before treatment. DNA methylation of this gene
was previously implicated in lipids [38, 39].
The increased power in the simulated data set, differ-
ence in findings between single-marker methods and
multimarker methods, and replicated multimarker
results in the literature give evidence that multimarker
methods are useful to increase power to detect epigen-
etic associations.
Conclusions of theme 3
The causal inference test is an appealing approach to
discover new mechanisms of action of SNPs, particularly
in previously TG-reported loci. It can be a promising
method for further understanding candidate EWAS
associations. There is a possibility for wider use and
application of gene-based tests to summarize SNP and
CpG estimates when analyzing methylation data.
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